Targeting EGFR tyrosine kinase inhibitors (EGFR-TKIs) for NSCLC promotes the emergence of acquired drug resistance, a major barrier to EGFR-targeted therapy (Johnson et al., 2022). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.